Holen Sie sich die Stockscreener-App
51.88
1.05%
0.55
Schlusskurs vom Vortag:
$51.33
Offen:
$51.69
24-Stunden-Volumen:
176.62K
Relative Volume:
0.11
Marktkapitalisierung:
$5.56B
Einnahmen:
$769.10M
Nettoeinkommen (Verlust:
$46.67M
KGV:
148.23
EPS:
0.35
Netto-Cashflow:
$119.79M
1W Leistung:
+11.33%
1M Leistung:
+26.98%
6M Leistung:
-29.00%
1J Leistung:
-26.68%
1-Tages-Spanne:
$51.00
$52.00
1-Wochen-Bereich:
$45.73
$52.50
52-Wochen-Spanne:
$28.66
$91.00
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
51.83 | 5.51B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
425.05 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
717.53 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.51 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.06 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.37 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | Eingeleitet | UBS | Neutral |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-06 | Hochstufung | Truist | Hold → Buy |
| 2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
| 2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-01 | Herabstufung | Truist | Buy → Hold |
| 2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-09-24 | Eingeleitet | Jefferies | Buy |
| 2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Bestätigt | Stifel | Hold |
| 2018-05-31 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Eingeleitet | Stifel | Buy |
| 2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2015-04-21 | Eingeleitet | FBR Capital | Outperform |
| 2014-01-13 | Herabstufung | Stifel | Buy → Hold |
| 2013-08-09 | Herabstufung | Janney | Buy → Neutral |
| 2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Corcept (NASDAQ: CORT) CEO sells 40K shares under 10b5-1 plan - Stock Titan
Corcept Therapeutics (NASDAQ: CORT) affiliate plans sale of 20,000 shares via Stifel - Stock Titan
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2026 Earnings Call Transcript - Insider Monkey
Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $75 - Moomoo
Corcept (CORT) Q1 2026 Earnings Transcript - The Globe and Mail
Corcept (CORT) Q4 2025 Earnings Transcript - The Globe and Mail
Corcept (CORT) Q1 2025 Earnings Transcript - The Globe and Mail
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures - TradingView
CORT Maintained by HC Wainwright & Co. -- Price Target Raised to $75 - GuruFocus
CORT DEADLINE: ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile
MSN Money - MSN
symbol__ Stock Quote Price and Forecast - CNN
Corcept (CORT) Upgraded After Key Regulatory Approval for Lifyorli - Yahoo Finance
Corcept Therapeutics Shakes Up Nasdaq Index Fund Radar - Kalkine Media
CORT Maintained by Piper Sandler -- Price Target Raised to $88 - GuruFocus
Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth - The Globe and Mail
Corcept Therapeutics Is Maintained at Overweight by Piper Sandler - Moomoo
Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 7.9%Time to Buy? - MarketBeat
Corcept Therapeutics (CORT) insider notifies sale of 40,000 shares via Stifel - Stock Titan
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised - The Globe and Mail
Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk - Benzinga
Corcept Therapeutics Incorporated Q1 2026 Earnings Call Summary - Yahoo Finance
Corcept Therapeutics Inc (CORT) Q1 2026 Earnings Call Highlights - GuruFocus
CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Corcept Therapeutics (NASDAQ:CORT) Announces Earnings Results - MarketBeat
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Corcept Therapeutics (CORT) Reports Promising Two-Year Survival Data - GuruFocus
Corcept Therapeutics (NASDAQ:CORT) Revenue Miss Leads to Q1 Net Loss, But Guidance Upgrade and Lifyorli Launch Signal Strong Momentum - ChartMill
Corcept Therapeutics Q1 Earnings Call Highlights - MarketBeat
CORT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Corcept Therapeutics (CORT) 8.8% Undervalued After Q1 2026 Mi - GuruFocus
Corcept Therapeutics Q1 2026 Earnings Call Transcript - Benzinga
Earnings call transcript: Corcept Therapeutics Q1 2026 raises guidance amid Lifyorli launch - Investing.com Canada
Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates - TradingView
Corcept: Q1 Earnings Snapshot - WKYC
Corcept Therapeutics Q1 Swings to Loss, Revenue Rises; Raises Full-Year Guidance - marketscreener.com
Earnings Flash (CORT) Corcept Therapeutics Posts Q1 Per Share Loss $-0.30 - marketscreener.com
(CORT) Corcept Therapeutics Expects 2026 Revenue Range $950M-$1.05B, vs. FactSet Est of $899.5M - marketscreener.com
Earnings Flash (CORT) Corcept Therapeutics Incorporated Reports Q1 Revenue $164.9M, vs. FactSet Est of $185.8M - marketscreener.com
Corcept reports survival data from ALS drug trial By Investing.com - Investing.com Canada
Higher costs and Lifyorli launch reshape Corcept (NASDAQ: CORT) in Q1 - Stock Titan
FDA cancer approval lifts Corcept (NASDAQ: CORT) 2026 outlook and spend - Stock Titan
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update - marketscreener.com
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis - Business Wire
Corcept earnings on deck: Can new cancer drug offset losses? By Investing.com - Investing.com Canada
Corcept Therapeutics Inc (CORT) - MSN
Corcept Earnings: What To Look For From CORT - Yahoo Finance
Corcept Therapeutics (CORT) Inspires Confidence with ROSELLA Phase 3 Survival Data - Insider Monkey
Corcept Therapeutics IncorporatedCommon Stock (NQ: CORT - FinancialContent
Corcept falls as appeals court sides with Teva in Korlym patent dispute - MSN
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):